Experimental CAR T-Cell therapy takes on progressive MS
NCT ID NCT06451159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation in the brain and spinal cord. The study will enroll 10 participants to find the safest dose and see if the therapy can reach the central nervous system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KYV-101 (a CAR T-cell therapy made from your own immune cells)
What this could lead to
If it works, this could point toward a new treatment option for people with progressive multiple sclerosis who haven't responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 10 participants, so it may not show clear benefit. There are also risks from the chemotherapy and the CAR T-cells themselves, including serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco, Multiple Sclerosis Center
San Francisco, California, 94158, United States